CJC-1295 5-MG

Description

Growth hormone-releasing hormone (GHRH) has undergone various structural modifications to develop analogues that retain selected biological effects while minimizing others. CJC-1295 is one such analogue, comprising the first 29 amino acids of GHRH. As a maleimido derivative of hGRF(1-29), CJC-1295 was engineered to enhance solubility and facilitate large-scale production, while maintaining the essential physiological functions of native GHRH.

CJC-1295 Versus CJC-1295 DAC

CJC-1295 is a modified form of the first 29 amino acids of GHRH, making it structurally similar to other GHRH analogues such as Sermorelin. While it closely resembles modified GRF (1-29), the two are not identical. Much of the confusion surrounding these peptides stems from their structural similarities and the fact that CJC-1295 was originally developed with an additional component known as the drug affinity complex (DAC).

DAC is attached to the peptide via a lysine linker and serves to protect the molecule during circulation in the bloodstream. By enabling binding to the abundant blood protein albumin, DAC significantly extends the half-life of CJC-1295 compared to shorter-acting analogues like GRF (1-29).

Half-life of CJC-1295-DAC compared to standard growth hormone releasing factor (GRF)
Source: Oxford Academic

Initially, ConjuChem Biotechnologies—the developer of the drug affinity complex (DAC)—referred to the DAC-containing molecule simply as CJC-1295. However, as versions of the peptide without DAC became available, this naming convention led to confusion. To clarify, the DAC-conjugated form is now commonly referred to as CJC-1295 with DAC or CJC-1295-DAC, while the version lacking DAC is referred to as CJC-1295 without DAC or CJC-1295-no DAC.

CJC-1295 Structure

Source: Oxford Academic

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.954 g/mol
PubChem CID: 56841945

CJC-1295-DAC Structure

Source: Oxford Academic

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-DAC
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3647.954 g/mol
PubChem CID: 91976842

CJC-1295 Research

CJC-1295 and Growth Hormone Release

As a derivative of GHRH, it should come as no surprise that CJC-1295 promotes the release of GH. Studies show that a single dose of CJC-1295 increase GH levels in mice by 2-10 times. Peak GH levels are reached approximately 2 hours after administration and the effects last for about six days. Unlike other GH secretagogues, CJC-1295 preserves normal physiologic release of GH^[1]. That means that the normal circadian peaks and valleys seen in GH release remain intact and that CJC-1295 is a physiologic growth hormone releasing factor.

Preserving physiologic release of GH even while influencing the maximum concentration of the hormone in the bloodstream is critical to ensuring enhanced effects without increased side effects. In particular, CJC-1295 has been demonstrated to preserve growth hormone’s physiologic effects on hyperplasia, hypertrophy, bone density, blood sugar, fat metabolism, protein synthesis, and myocardial (heart cell) function.

CJC-1295 and Growth

Studies in mice without normal GHRH physiology have shown that CJC-1295 preserves normal GH release^[2]. This makes the peptide potentially useful as a therapy for abnormal growth in a variety of mammalian species, humans included. Preserving normal pulsatile release of GH is critical to ensuring that proper release of downstream hormones, such as insulin-life growth factor-2 (IGF-1).

CJC-1295 and Infertility

Research from the early 1990s suggests that CJC-1295 and other GRF analogues may be useful in promoting ovulation in infertile female patients. Scientists have long known that ovulation is dependent on IGF-1 and that it is also likely influenced by GH release and cycling. Research in animal models of superovulation has helped to confirm these theories by showing that both GH and IGF-1 levels rise significantly surrounding the time of ovulation. Further, these studies indicate that exogenous administration of GH secretagogues, like CJC-1295, is enough to cause appropriate ovulation^[3]. There is some speculation that CJC-1295 and other analogues may even be useful in male infertility by helping to regulate sperm production. This latter hypothesis has yet to be tested.

Scientific Journal Author

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [4] under the referenced citations.

Referenced Citations

1. M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006.
2. M. Alba et al., “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse,” Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006.
3. A. Volpe, G. Coukos, A. Barreca, G. Giordano, P. G. Artini, and A. R. Genazzani, “Clinical use of growth hormone-releasing factor for induction of superovulation,” Hum. Reprod., vol. 6, no. 9, pp. 1228–1232, Oct. 1991.
4. Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.

Disclaimer: All articles and product information provided on this website are intended solely for informational and educational purposes.

The products available on this site are supplied strictly for in-vitro research use only. In-vitro studies—meaning “in glass”—are conducted outside of living organisms. These products are not medications or therapeutic agents and have not been evaluated or approved by the FDA for the diagnosis, treatment, prevention, or cure of any disease or medical condition. Any form of bodily administration to humans or animals is strictly prohibited by law.